v3.26.3
Segment Performance Measures and Expenses (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Significant Expense Categories and Consolidated Net Loss

The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

 

   2026   2025         
   For the Nine Months Ended September 30, 
   (Thousands)   Change Increase (Decrease) 
   2026   2025         
Operating Expenses:                    
Clinical Research                    
OVATION Trials (Phase 2 & 3)  $774   $800   $(26)   -3%
MRD Study   169    106    63    59%
PlaCCine Vaccine Phase 1 Trial   -    42    (42)   -100%
Other Clinical and Regulatory   1,379    1,387    (8)   -1%
Subtotal   2,322    2,335    (13)   -1%
Non-Clinical R&D and CMC                    
Manufacturing & Clinical Supply   3,272    2,955    317    11%
Subtotal   3,272    2,955    317    11%
                     
Research and development expenses   5,594    5,290    304    6%
General and administrative expenses   4,951    5,098    (147)   -3%
Total operating expenses   10,545    10,388    157    2%
                     
Loss from operations  $10,545   $10,388   $157    2%